Eli Lilly agreed to buy Engage Biologics, paying up to $202 million to add a preclinical non-viral DNA delivery platform to its genetic medicine pipeline. Engage’s Tethosome approach uses lipid nanoparticles rather than viral vectors and incorporates an mRNA component for protein-mediated delivery to the nucleus. Lilly’s deal extends a run of genetics-focused transactions intended to broaden modality access and address recurring AAV adoption constraints, including safety and manufacturing complexity. Engage brings platform assets alongside prior seed funding from investors including the Gates Foundation and the Cystic Fibrosis Foundation, positioning the technology for later translation across genetic indications. For the market, the acquisition underscores that companies are increasingly competing on delivery systems as much as therapeutic payloads—particularly for gene-based medicines aiming for improved tolerability and redosability.